Sort by

Send to

Choose Destination

Links from PubMed

Items: 15


Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients.

Chidi AP, Bryce CL, Donohue JM, Fine MJ, Landsittel DP, Myaskovsky L, Rogal SS, Switzer GE, Tsung A, Smith KJ.

Value Health. 2016 Jun;19(4):326-34. doi: 10.1016/j.jval.2016.01.010. Epub 2016 Mar 24.


Changes in circulating lipids level over time after acquiring HCV infection: results from ERCHIVES.

Butt AA, Yan P, Simon TG, Chung RT, Abou-Samra AB; ERCHIVES study team.

BMC Infect Dis. 2015 Nov 11;15:510. doi: 10.1186/s12879-015-1268-2.


Cost-effectiveness of new antiviral regimens for treatment-naïve U.S. veterans with hepatitis C.

Chidi AP, Rogal S, Bryce CL, Fine MJ, Good CB, Myaskovsky L, Rustgi VK, Tsung A, Smith KJ.

Hepatology. 2016 Feb;63(2):428-36. doi: 10.1002/hep.28327. Epub 2015 Dec 21.


Qualitative analysis of patient-centered decision attributes associated with initiating hepatitis C treatment.

Zuchowski JL, Hamilton AB, Pyne JM, Clark JA, Naik AD, Smith DL, Kanwal F.

BMC Gastroenterol. 2015 Oct 1;15:124. doi: 10.1186/s12876-015-0356-5.


Psychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implications.

Hauser P, Kern S.

World J Hepatol. 2015 Jul 28;7(15):1921-35. doi: 10.4254/wjh.v7.i15.1921. Review.


Predictors of Mortality among United States Veterans with Human Immunodeficiency Virus and Hepatitis C Virus Coinfection.

Erqou S, Mohanty A, Murtaza Kasi P, Butt AA.

ISRN Gastroenterol. 2014 Apr 7;2014:764540. doi: 10.1155/2014/764540. eCollection 2014.


Nonresponse to interferon-α based treatment for chronic hepatitis C infection is associated with increased hazard of cirrhosis.

Cozen ML, Ryan JC, Shen H, Lerrigo R, Yee RM, Sheen E, Wu R, Monto A.

PLoS One. 2013 Apr 25;8(4):e61568. doi: 10.1371/journal.pone.0061568. Print 2013.


Hepatitis C screening: getting it right.

Edlin BR.

Hepatology. 2013 Apr;57(4):1644-50. doi: 10.1002/hep.26194. Epub 2012 Dec 24.


Cost-effectiveness and population outcomes of general population screening for hepatitis C.

Coffin PO, Scott JD, Golden MR, Sullivan SD.

Clin Infect Dis. 2012 May;54(9):1259-71. doi: 10.1093/cid/cis011. Epub 2012 Mar 12.


The incidence, predictors and management of anaemia and its association with virological response in HCV / HIV coinfected persons treated with long-term pegylated interferon alfa 2a and ribavirin.

Butt AA, Umbleja T, Andersen JW, Chung RT, Sherman KE; ACTG A5178 Study Team.

Aliment Pharmacol Ther. 2011 Jun;33(11):1234-44. doi: 10.1111/j.1365-2036.2011.04648.x. Epub 2011 Mar 29.


Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease.

Butt AA, Chang CC, Kuller L, Goetz MB, Leaf D, Rimland D, Gibert CL, Oursler KK, Rodriguez-Barradas MC, Lim J, Kazis LE, Gottlieb S, Justice AC, Freiberg MS.

Arch Intern Med. 2011 Apr 25;171(8):737-43. doi: 10.1001/archinternmed.2011.151.


A comparison of treatment eligibility for hepatitis C virus in HCV-monoinfected versus HCV/HIV-coinfected persons in electronically retrieved cohort of HCV-infected veterans.

Butt AA, McGinnis K, Skanderson M, Justice AC.

AIDS Res Hum Retroviruses. 2011 Sep;27(9):973-9. doi: 10.1089/AID.2011.0004. Epub 2011 Mar 18.


Gene therapeutic approach for inhibiting hepatitis C virus replication using a recombinant protein that controls interferon expression.

Joo CH, Lee U, Nam YR, Jung JU, Lee H, Cho YK, Kim YK.

Antimicrob Agents Chemother. 2010 Dec;54(12):5048-56. doi: 10.1128/AAC.00682-10. Epub 2010 Sep 20.


Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response.

Chak E, Saab S.

Curr Hepat Rep. 2010 Aug;9(3):147-154. Epub 2010 Jun 19.


Hepatitis C treatment completion rates in routine clinical care.

Butt AA, McGinnis KA, Skanderson M, Justice AC.

Liver Int. 2010 Feb;30(2):240-50. doi: 10.1111/j.1478-3231.2009.02156.x. Epub 2009 Nov 4.

Items per page

Supplemental Content

Write to the Help Desk